Free Trial

Bolt Biotherapeutics Q4 2023 Earnings Report

Bolt Biotherapeutics logo
$0.51 -0.01 (-1.61%)
As of 01/17/2025 04:00 PM Eastern

Bolt Biotherapeutics EPS Results

Actual EPS
-$0.47
Consensus EPS
-$0.47
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Bolt Biotherapeutics Revenue Results

Actual Revenue
$2.09 million
Expected Revenue
$1.97 million
Beat/Miss
Beat by +$120.00 thousand
YoY Revenue Growth
N/A

Bolt Biotherapeutics Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Bolt Biotherapeutics Earnings Headlines

Outperform BTC without owning any crypto?
I want to let you in on what may be the hottest crypto discovery of all time… One that has NOTHING to do with creating a crypto wallet or touching ANY risky coin for that matter. Instead, it’s a way that could let regular folks like you and me target 10X the possible results you’d expect from buying Bitcoin … in just a fraction of the time It sounds nuts… trust me I know that… But just as I would hate for you to jump into any risky crypto asset… That’s exactly how I would hate for you to miss out on what could be a safer and better way to benefit from the crypto bull run of 2024. Which is why I’m giving you an opportunity to get all the details of this iconic crypto discovery with you for the first time ever… completely free…
Bolt Biotherapeutics Reports Q3 2024 Financial Results
See More Bolt Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bolt Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bolt Biotherapeutics and other key companies, straight to your email.

About Bolt Biotherapeutics

Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

View Bolt Biotherapeutics Profile

More Earnings Resources from MarketBeat